10375 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
Conditions: Recurrent Bladder Cancer;   Stage I Bladder Cancer;   Stage II Bladder Cancer;   Stage III Bladder Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: placebo;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
2 Terminated Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Drug: vemurafenib;   Other: laboratory biomarker analysis;   Other: pharmacological study
3 Completed Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
Conditions: Breast Cancer;   Cervical Cancer;   Colorectal Cancer;   Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer
Interventions: Biological: aldesleukin;   Biological: mutant p53 peptide pulsed dendritic cell vaccine;   Biological: ras peptide cancer vaccine;   Biological: sargramostim;   Biological: therapeutic autologous lymphocytes;   Biological: therapeutic tumor infiltrating lymphocytes
4 Completed PS-341 in Treating Women With Metastatic Breast Cancer
Conditions: Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: bortezomib;   Other: laboratory biomarker analysis
5 Active, not recruiting Decitabine in Treating Patients With Myelofibrosis
Condition: Primary Myelofibrosis
Intervention: Drug: decitabine
6 Terminated Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
Conditions: Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: thalidomide
7 Active, not recruiting Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: leuprolide acetate;   Drug: goserelin acetate;   Drug: vismodegib;   Other: laboratory biomarker analysis
8 Active, not recruiting Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Drug: vismodegib;   Other: pharmacological study
9 Active, not recruiting Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Gastrointestinal Stromal Tumor;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Gastric Cancer;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: cetuximab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
10 Terminated Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alvocidib;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Active, not recruiting Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: bortezomib;   Drug: alvocidib;   Other: pharmacological study
12 Recruiting Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab;   Drug: tivantinib;   Other: laboratory biomarker analysis
13 Completed Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: ixabepilone;   Drug: mitoxantrone hydrochloride;   Drug: prednisone
14 Completed Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Conditions: Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Endometrial Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: temsirolimus;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Completed A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: topotecan hydrochloride;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Active, not recruiting Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
Conditions: Adenomatous Polyp;   Colorectal Cancer
Interventions: Drug: macrogol 3350-based oral osmotic laxative;   Other: placebo;   Other: laboratory biomarker analysis
17 Completed Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
Condition: Sarcoma
Intervention: Drug: nicotine
18 Completed
Has Results
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
Condition: Untreated Childhood Brain Stem Glioma
Interventions: Drug: motexafin gadolinium;   Radiation: 3-dimensional conformal radiation therapy
19 Completed Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Condition: Recurrent Endometrial Carcinoma
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
20 Completed VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Tumor
Intervention: Biological: ziv-aflibercept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years